



## Curriculum Vitae di Francesco Cusano

### INFORMAZIONI PERSONALI

Nome	FRANCESCO CUSANO
Data e luogo di nascita	17/05/1954 – Benevento
Codice Fiscale	CSNFNC54E17A783Q
Iscrizione OO.MM.	Benevento con n° 1304
Indirizzo di casa	VIA NICOLA CALANDRA, 3- 82100 BENEVENTO
Telefono	+390824 57459 - 3384603707
Fax	+390824 57459
E-mail	drfrancescocusano@gmail.com
Esperienze e Responsabilità lavorativa	
Dal 11-7-2001 ad oggi	Direttore Struttura Complessa – UOC di Dermatologia A.O.R.N. “San Pio” – P.O. “ G. Rummo” Via dell’Angelo, 1- 82100 Benevento
Dal 1-6-98 al 31-7-98	Dirigente Medico con funzione di Direttore presso UOC Dermatologia A.O.R.N. “San Pio” – P.O. “ G. Rummo” Via dell’Angelo, 1 - 82100 Benevento Allievo interno, poi tesista, specializzando, infine contrattista (“gettonato”) presso la Clinica Dermatologica dell’Università Federico II di Napoli
Formazione e Titoli Professionali	
Il 29-10-80	Laurea in Medicina e Chirurgia presso la II Facoltà dell’Università di Napoli “Federico II” con votazione 110/110

Il 26-7-83	Specializzazione in Dermatologia e Venereologia presso la II Facoltà dell'Università di Napoli "Federico II" con votazione 89/90
	Allievo interno, poi tesista, specializzando, infine contrattista ("gettonato") presso la Clinica Dermatologica dell'Università Federico II di Napoli
Dal 1976-1985	Revisore dei Conti , Consigliere (9 anni), tesoriere (6 anni), Segretario (3 anni), Vicepresidente (6 anni) dell'Ordine dei Medici-Chirurghi della Provincia di Benevento;
Dal 1988al 1990	Membro del Comitato Scientifico del Gruppo Italiano Ricerca Dermatiti da Contatto ed Ambientali (GIRDCA);
Dal 1993 al 1998	Membro del Comitato Scientifico del Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED);
Dal 1994 al 2000	Rappresentante Regionale ADOI;
Dal 2008 al 2012	Segretario del Consiglio Nazionale ADOI;
Dal 2018 ad oggi	Presidente Nazionale ADOI;
Altre informazioni	<ol style="list-style-type: none"> <li>1) Attività didattica presso la scuola di Specializzazione in dermatologia e venereologia dell'Università di Federico II (7 anni);</li> <li>2) Attività didattica teorico-pratica per gli studenti del V anno di corso di laurea in Medicina e Chirurgia dell'Università Federico II di Napoli (3 anni);</li> <li>3) Insegnamento presso la scuola per infermieri professionali e presso la scuola per terapisti della Riabilitazione AO Rummo di Benevento (14 anni);</li> <li>4) Componente del gruppo promotore e del panel di esperti del sistema nazionale Linee Guida dell'istituto Superiore di Sanità per la stesura di Linee Guida in dermatologia;</li> <li>5) Socio di varie associazioni e società scientifiche e gruppi di studio;</li> <li>6) Socio Fondatore , Delegato regionale (2 anni), e Consigliere nazionale (3 anni) della SIDAPA ( Società Italiana di dermatologia Allergologica Professionale e Ambientale);</li> </ol>

- 1) **Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDEmaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA).**  
Patruno C, Amerio P, Chiricozzi A, Costanzo A, Cristaudo A, **Cusano F**, Foti C, Girolomoni G, Guarneri F, Naldi L, Offidani A, Pigatto P, Prignano F, Stingeni L, Calzavara Pinton P.G Ital Dermatol Venereol. 2019 Dec 16. doi: 10.23736/S0392-0488.19.06522-2.
- 2) **Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.**  
Fargnoli MC, Esposito M, Ferrucci S, Girolomoni G, Offidani A, Patrizi A, Peris K, Costanzo A, Malara G, Pellacani G, Romanelli M, Amerio P, Cristaudo A, Flori ML, Motolese A, Betto P, Patruno C, Pigatto P, Sirna R, Stinco G, Zalaudek I, Bianchi L, Boccaletti V, Cannavò SP, Cusano F, Lembo S, Mozzillo R, Gallo R, Potenza C, Rongioletti F, Tiberio R, Grieco T, Micali G, Persechino S, Pettinato M, Pucci S, Savi E, Stingeni L, Romano A, Argenziano G; Dupilumab Italian National Access Program (Dup-INAP group).J Dermatolog Treat. 2019 Oct 28;1-doi:10.1080/09546634.2019.1682503
- 3) **Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis).**  
Damiani G, Calzavara-Pinton P, Stingeni L, Hansel K, Cusano F; "Skin Allergy" Group of SIDEmaST; "ADOI" (Associazione Dermatologi Ospedalieri Italiani); "SIDAPA" (Società Italiana di Dermatologia Allergologica, Professionale e Ambientale), Pigatto PDM.Dermatol Ther. 2019 Nov;32(6):e13121. doi: 10.1111/dth.13121. Epub 2019 Nov 7
- 4) **Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light.**  
Riberio S, Dapavo P, Casalegno C; HS Awareness Working Group.  
J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:7-9. doi: 10.1111/jdv.15828. PMID: 10.1111/jdv.15828.
- 5) **Age and gender influence on HIDRADisk outcomes in adalimumab-treated hidradenitis suppurativa patients.**  
Fabbrocini G, Marasca C, Megna M, Peris K; HS Quality of Life Study Group.  
J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:25-27. doi: 10.1111/jdv.15821. PMID: 10.1111/jdv.15821.
- 6) **Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.**  
Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, Galluccio AG, Gambardella A, Lembo S, Mozzillo R, Scotto Di Luzio G, Fabbrocini G, Balato N. Expert Opin Biol Ther. 2019 Aug;19(8):855-861. doi:10.1080/14712598.2019.1622678. Epub 2019 May 29.PMID: 10.1080/14712598.2019.1622678.
- 7) **Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study.**  
Papini M, Cusano F, Romanelli M, Burlando M, Stinco G, Girolomoni G, Peris K, Potenza C, Offidani A, Bartezaghi M, Aloisi E, Costanzo A; SUPREME study group.  
Br J Dermatol. 2019 Aug;181(2):413-414. doi: 10.1111/bjd.18013. Epub 2019 May 29.
- 8) **Atopic dermatitis in young adult italian males: persistent and adult-onset varieties did not differ clinically and as for allergological variables.**  
Ingordo V, Cazzaniga S, Naldi L, Perrucci S, Barbierato M, Crociata F, Cusano F. G Ital Dermatol Venereol. 2019 Jan 16. doi: 10.23736/S0392-0488.18.06239-9. [Epub ahead of print]
- 9) **"Paradoxical joint inflammation" possibly induced by a tumor necrosis factor antagonist in three patients with psoriasis.**  
Di Costanzo L, Ferrucci MG, Cusano F. G Ital Dermatol Venereol. 2019 Jan 9. doi: 10.23736/S0392-0488.18.06028-5. [Epub ahead of print]

- 10) **HIDRADisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.** Peris K, Lo Schiavo A, Fabbrocini G, Dini V, Patrizi A, Fusano M, Bianchi L, Guanziroli E, Guarneri C, Parodi A, Bertoldi A, Musumeci ML, Offidani A, Rongioletti F, Pistone G, Malara G, Potenza C, Casari A, Franchi C, Ardigò M, **Cusano F**, Stingeni L, Amerio P, Mancini LL, Prignano F, Deboli T, Gualberti G, Saragaglia V, Bettoli V. *J Eur Acad Dermatol Venereol.* 2019 Jan 11. doi: 10.1111/jdv.15425.
- 11) **Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.** Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartzaghi M, Carraro L, Castellino G; SUPREME Study Group. *Br J Dermatol.* 2018 Nov;179(5):1072-1080.
- 12) **Neglected skin carcinomas and Vismodegib: our experience.** Russo F, Mancini V, Taddeucci P, Cirocco A, **Cusano F**, Pellegrino M, Sirna R. *G Ital Dermatol Venereol.* 2018 Feb 7. doi: 10.23736/S0392-0488.18.05873-X. [Epub ahead of print]
- 13) **The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients.** Colombo D, Banfi G, Cassano N, Graziottin A, Vena GA, Fiori GG, Zagni E, Stingeni L, Chimenti S, Berardesca E, Micali G, Albertini G, De Simone C, Bellia G; GENDER ATTENTION study group. *Adv Ther.* 2017 Jun;34(6):1349-1363.
- 14) **Adult female acne and associated risk factors: Results of a multicenter case-control study in Italy.** Di Landro A, Cazzaniga S, **Cusano F**, Bonci A, Carla C, Musumeci ML, Patrizi A, Bettoli V, Pezzarossa E, Caproni M, Fortina AB, Campione E, Ingordo V, Naldi L; Group for Epidemiologic Research in Dermatology Acne Study Group. *J Am Acad Dermatol.* 2016 Dec;75(6):1134-1141.
- 15) **MANAGEMENT OF PSORIATIC ARTHRITIS: SHOULD THE INTERACTION BETWEEN DERMATOLOGISTS AND RHEUMATOLOGISTS IN CLINICAL PRACTICE BE INTENSIFIED?** Migliore A, **Cusano F**, Bianchi G, Malara G, Epis O, De Pità O. *J Biol Regul Homeost Agents.* 2015 Jul-Sep;29(3):547-61.
- 16) **Follicular psoriasis: an under-recognized condition.** Babino G, Moscarella E, Longo C, Lallas A, Ferrara G, Cusano F, Cinotti E, Argenziano G. *J Eur Acad Dermatol Venereol.* 2016 Aug;30(8):1397-9.
- 17) **Biosimilar infliximab: an expert view.** Genazzani A, Altomare G, Balato N, Cusano F, De Pità O, Loconsole F, Micali G, Piaserico S, Girolomoni G. *G Ital Dermatol Venereol.* 2015 Aug;150(4):449-59.
- 18) **The constellation of dietary factors in adolescent acne: a semantic connectivity map approach.** Grossi E, Cazzaniga S, Crotti S, Naldi L, Di Landro A, Ingordo V, Cusano F, Atzori L, Tripodi Cutri F, Musumeci ML, Pezzarossa E, Bettoli V, Caproni M, Bonci A; GISED Acne Study Group. *J Eur Acad Dermatol Venereol.* 2016 Jan;30(1):96-100.
- 19) **Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry.** Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group. *Br J Dermatol.* 2015 Jun;172(6):1613-20. Erratum in: *Br J Dermatol.* 2017 May;176(5):1415-1416.
- 20) **A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides.** Ferrara G, Pancione M, Votino C, Quaglino P, Tomasini C, Santucci M, Pimpinelli N, Cusano F, Sabatino L, Colantuoni V. *Br J Dermatol.* 2014 Jun;170(6):1266-75.
- 21) **Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.** Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L; Psocare Study Group. *J Am Acad Dermatol.* 2014 Feb;70(2):257-62.
- 22) **Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries.** Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, Spuls PI, Naldi L; Psonet Network. *Br J Dermatol.* 2013 Sep;169(3):710-4.

- 23) Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults.**  
Di Landro A, Cazzaniga S, Parazzini F, Ingordo V, Cusano F, Atzori L, Cutri FT, Musumeci ML, Zinetti C, Pezzarossa E, Bettoli V, Caproni M, Lo Scocco G, Bonci A, Bencini P, Naldi L; GISED Acne Study Group. *J Am Acad Dermatol.* 2012 Dec;67(6):1129-35.
- 24) Dermatology Life Quality Index score in vitiligo patients: a pilot study among young Italian males.**  
Ingordo V, Cazzaniga S, Gentile C, Iannazzone SS, Cusano F, Naldi L. *G Ital Dermatol Venereol.* 2012 Feb;147(1):83-90.
- 25) Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.**  
Gisoni P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group. *J Eur Acad Dermatol Venereol.* 2013 Jan;27(1):e30-41.
- 26) Italian Euromelanoma Day Screening Campaign (2005-2007) and the planning of melanoma screening strategies.**  
Seidenari S, Benati E, Ponti G, Borsari S, Ferrari C, Albertini G, Altomare G, Arcangeli F, Aste N, Bernengo MG, Bongiorno MR, Borroni G, Calvieri S, Chimenti S, **Cusano F**, Fracchiolla C, Gaddoni G, Girolomoni G, Guarneri B, Lanzoni A, Lombardi M, Lotti T, Mariotti A, Marsili F, Micali G, Parodi A, Peris K, Peserico A, Quaglino P, Santini M, Schiavon S, Tonino C, Trevisan G, Tribuzi P, Valentini P, Vena GA, Virgili A. *Eur J Cancer Prev.* 2012 Jan;21(1):89-95.
- 27) Primary cutaneous marginal zone B-cell lymphoma with anetoderma: spontaneous involution plus de novo clonal expansion.**  
Ferrara G, **Cusano F**, Robson A, Stefanato CM. *J Cutan Pathol.* 2011 Apr;38(4):342-5.
- 28) Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males.**  
Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. *J Eur Acad Dermatol Venereol.* 2011 Jan;25(1):105-9.
- 29) Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Cusano F, Iannazzone SS, Riccio G, Piccirillo F. Eur J Dermatol. 2010 Jul-Aug;20(4):520.**
- 30) Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation.**  
Naldi L, Parazzini F, Gallus S; GISED Study Centres. *Acta Derm Venereol.* 2009;89(2):122-5.
- 31) Erlotinib-induced pustular eruption. Cusano F, Ferrara G, Barletta E, Ingordo V. G Ital Dermatol Venereol. 2009 Feb;144(1):93-6.**
- 32) Reproducibility of dermoscopic features of congenital melanocytic nevi.**  
Ingordo V, Iannazzone SS, **Cusano F**, Naldi L. *Dermatology.* 2008;217(3):231-4.
- 33) Distribution of congenital melanocytic naevi and congenital naevus-like naevi in a survey of 3406 Italian schoolchildren.** Gallus S, Naldi L; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology. *Br J Dermatol.* 2008 Aug;159(2):433-8.
- 34) A case of Stevens-Johnson syndrome possibly induced by amifostine during radiotherapy.**  
Zollo E, **Cusano F**, Argenone A, Cusano CI, Pelosi P, Pironti T, Spacagna E, Viscusi A, Lioce M. *Tumori.* 2007 Nov-Dec;93(6):634-5.
- 35) Efficacy vs. effectiveness--docetaxel and prednisone in hormone refractory prostate cancer.** Howard DN, Chambers C, Cusano F. *J Oncol Pharm Pract.* 2008 Mar;14(1):45-9.
- 36) Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study.** Pelucchi C, Naldi L, Di Landro A, La Vecchia C; Oncology Study Group of Italian Group for Epidemiologic Research in Dermatology. *Dermatology.* 2008;216(3):271-6.
- 37) Fiberglass dermatitis microepidemic in a primary school.** Cusano F, Mariano M. *Contact Dermatitis.* 2007 Nov;57(5):351-2.
- 38) The 'EpiEnlist' project: a dermo-epidemiologic study on a representative sample of young Italian males. Prevalence of selected pigmentary lesions.** Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. *J Eur Acad Dermatol Venereol.* 2007 Sep;21(8):1091-6.
- 39) Congenital melanocytic nevus: an epidemiologic study in Italy.** Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. *Dermatology.* 2007;214(3):227-30.
- 40) Clinicopathologic features of systemic contact dermatitis from ethylenediamine in cetirizine and levocetirizine.** Cusano F, Ferrara G, Crisman G, Sarracco G, Zalaudek I, Argenziano G. *Dermatology.* 2006;213(4):353-5.


- 41) **Dermoscopic features of congenital melanocytic nevus and Becker nevus in an adult male population: an analysis with a 10-fold magnification.** Ingordo V, Iannazzone SS, Cusano F, Naldi L. *Dermatology*. 2006;212(4):354-60.
- 42) **A pilot study of a combined dermoscopic-pathological approach to the telediagnosis of melanocytic skin neoplasms.** Ferrara G, Argenziano G, Cerroni L, Cusano F, Di Blasi A, Urso C, Soyer HP. *J Telemed Telecare*. 2004;10(1):34-8.
- 43) **Lymphatic spread of melanoma mimicking Kaposi-like angiodermatitis.** Ferrara G, Sarracco G, Erbazzi A, Argenziano G, Cusano F. *Br J Dermatol*. 2003 Oct;149(4):909-10.
- 44) **Clinical relevance of contact sensitization in atopic dermatitis.** Ingordo V, D'Andria G, D'Andria C, Cusano F. *Contact Dermatitis*. 2001 Oct;45(4):239-40.
- 45) **Post-apoplectic trigeminal trophic syndrome.** Ferrara G, Argenziano G, Cicarelli G, Cusano F, Delfino M. *J Eur Acad Dermatol Venereol*. 2001 Mar;15(2):153-5.
- 46) **Effectiveness of disperse dyes mix in detection of contact allergy to textile dyes: an Italian multicentre study.** Francalanci S, Angelini G, Balato N, Berardesca E, Cusano F, Gaddoni G, Lisi P, Lodi A, Schena D, Sertoli A. *Contact Dermatitis*. 1995 Nov;33(5):351.
- 47) **Contact dermatitis from pilocarpine.** Cusano F, Luciano S, Capozzi M, Verrilli DA. *Contact Dermatitis*. 1993 Aug;29(2):99.
- 48) **Allergic contact dermatitis from transdermal nicotine systems.** Vincenzi C, Tosti A, Cirone M, Guarrera M, Cusano F. *Contact Dermatitis*. 1993 Aug;29(2):104-5.
- 49) **Topical NSAID allergic contact dermatitis. Italian experience.** Pigatto PD, Mozzanica N, Bigardi AS, Legori A, Valsecchi R, Cusano F, Tosti A, Guarrera M, Balato N, Sertoli A. *Contact Dermatitis*. 1993 Jul;29(1):39-41.
- 50) **Contact allergy to benzalkonium chloride and glutaraldehyde in a dental nurse.** Cusano F, Luciano S. *Contact Dermatitis*. 1993 Feb;28(2):127.
- 51) **Contact dermatitis from feprazone.** Cusano F, Luciano S, Iannazzone S, Adamo F. *Contact Dermatitis*. 1993 Feb;28(2):109.
- 52) **Contact dermatitis from pramoxine.** Cusano F, Luciano S. *Contact Dermatitis*. 1993 Jan;28(1):39.
- 53) **Allergic contact dermatitis from coal tar.** Cusano F, Capozzi M, Errico G. *Contact Dermatitis*. 1992 Jul;27(1):51-2.
- 54) **Photocontact dermatitis from ketoprofen with cross-reactivity to ibuprofen.** Cusano F, Capozzi M. *Contact Dermatitis*. 1992 Jul;27(1):50-1.
- 55) **Contact Dermatitis.** 1992 Jul;27(1):50-1.
- 56) **Familial progeria or mandibulo-acral dysplasia?** Cusano F, Scarano G. *Am J Med Genet*. 1991 Oct 1;41(1):139.
- 57) **[Melkersson-Rosenthal syndrome. A case treated with clofazimine].** Cusano F, Lamparelli A, Errico A, Errico G. *Minerva Stomatol*. 1991 Sep;40(9):569-72.
- 58) **[Localized primary cutaneous nodular amyloidosis].** Ferrara G, Cusano F, Capozzi M, De Dominicis G. *Pathologica*. 1991 Jul-Aug;83(1086):485-9.
- 59) **[Bamifylline induced exanthema].** Ferri C, Reseghetti A, Veraldi S, Cusano F, Naldi L, Caputo R, Cainelli T. *Ann Dermatol Venereol*. 1991;118(9):635-6.
- 60) **Contact dermatitis from dexchlorpheniramine.** Cusano F, Capozzi M, Errico G. *Contact Dermatitis*. 1989 Nov;21(5):340.
- 61) **[Allergic dermatitis caused by contact with ethylenediamine].** Balato N, Cusano F, Lembo G, Patri P, Ayala F. *G Ital Dermatol Venereol*. 1987 Nov;122(11):583-8.
- 62) **Photo-contact dermatitis from ketoprofen.** Cusano F, Rafenelli A, Bacchilega R, Errico G. *Contact Dermatitis*. 1987 Aug;17(2):108-9.
- 63) **Safety of propyl gallate in topical products.** Cusano F, Capozzi M, Errico G. *J Am Acad Dermatol*. 1987 Aug;17(2 Pt 1):308-10.
- 64) **[Cutis verticis gyrata and dystrophia myotonica].** Cusano F, Feleppa M, Capozzi M, Errico G. *G Ital Dermatol Venereol*. 1987 Apr;122(4):201.
- 65) **Contact dermatitis from nifuratel.** Cusano F, Capozzi M, di Giulio P, Errico G. *Contact Dermatitis*. 1987 Jan;16(1):37.
- 66) **Ethylenediamine dermatitis.** Balato N, Cusano F, Lembo G, Ayala F. *Contact Dermatitis*. 1986 Nov;15(5):263-5.
- 67) **[3 cases of allergic reaction to aminophylline].** Cusano F, Capozzi M, Errico G. *G Ital Dermatol Venereol*. 1986 Nov-Dec;121(6):443-5.
- 68) **Tyrosinemia type II in two cases previously reported as Richner-Hanhart syndrome.** Balato N, Cusano F, Lembo G, Santoianni P. *Dermatologica*. 1986;173(2):66-74.

- 69) **Why patients allergic to ethylenediamine do not react to topical steroids containing ethylenediamine.** Balato N, Cusano F. Arch Dermatol. 1984 Sep;120(9):1139-40.
- 70) **Ethylenediamine contact dermatitis.** Balato N, Cusano F, Lembo G, Ayala F. Contact Dermatitis. 1984 Aug;11(2):112-4.
- 71) **Lichen planus and ulcerative colitis.** Cusano F, Errico G. Arch Dermatol. 1984 Aug;120(8):994-5.
- 72) **Allergic dermatitis from Viruserol ointment probably due to tromantadine hydrochloride.** Lembo G, Balato N, Cusano F, Ayala F. Contact Dermatitis. 1984 May;10(5):317.
- 73) **Contact dermatitis from pyrrolenitrin.** Balato N, Lembo G, Cusano F, Ayala F. Contact Dermatitis. 1983 May;9(3):238.
- 74) **Unusual formaldehyde dermatitis.** Lembo G, Balato N, Cusano F. Contact Dermatitis. 1982 Jul;8(4):272.

*Autorizzo il trattamento dei miei dati personali ai sensi del D.lgs. 196 del 30 giugno 2003.*

**Data e luogo di sottoscrizione:** \_Benevento, 6 maggio 2026

***Dott. Francesco Cusano***

A handwritten signature in blue ink, appearing to read 'Francesco Cusano', is written over a faint, light blue circular stamp or watermark.